公开(公告)号：JPH08311098A

公开(公告)日：1996-11-26

申请号：JP14674295

申请日：1995-05-22

Applicant: DAICEL CHEM ,  FUJISAWA PHARMACEUTICAL CO

Inventor： KIMURA HITOSHI ,  KAWAMOTO TAKAFUMI ,  ITO MASAAKI ,  SENOO HACHIRO ,  SEKI NOBUO

IPC: A61K38/00 ,  A61P37/06 ,  C07K5/09 ,  C07K5/107 ,  C07K7/06

Abstract: PURPOSE: To obtain a peptide or its derivative composed of relatively small number of constituent amino acids, exhibiting antagonistic action on IL-6 and capable of inhibiting the development of the activity and to provide an IL-6 antagonistic agent containing the peptide. CONSTITUTION: The objective peptide is a pentapeptide expressed by general formula (I): X-A-B-D-Y (X is hydrogen, an amino-protecting group, an amino acid residue or a peptide residue consisting of 2-10 amino acids bonded with each other; Y is hydroxyl, amino, a carboxyl-protecting group, an amino acid residue or a peptide residue consisting of 2-5 amino acids bonded with each other; A is Arg residue or other amino acid residue optionally having a protective group on guanidino group; D is Arg residue optionally having a protective group on guanidino group; B is Leu residue or other amino acid residue including non-natural amino acid and optionally having protective group on the side chain functional group of the amino acid). The present invention also relates to an interleukin-6 antagonistic agent containing the pentapeptide.

公开(公告)号：JP2003201301A

公开(公告)日：2003-07-18

申请号：JP2002070022

申请日：2002-03-14

Applicant: DAICEL CHEM

Inventor： SHIBATA TORU ,  SHUDO YUICHIRO ,  ITO MASAAKI ,  ASAI TANEMI

IPC: C08B3/06 ,  C08J5/18

Abstract: PROBLEM TO BE SOLVED: To appropriately adjust the intermolecular and the intramolecular (a glucose unit) acetylation degree of an acetyl cellulose. SOLUTION: In aging a cellulose acetate in the presence of an acetylation agent and a catalyst, the amount of water or an alcohol present is adjusted to 0.1-10 mol% based on the acetylation agent. COPYRIGHT: (C)2003,JPO

公开(公告)号：JP2001002763A

公开(公告)日：2001-01-09

申请号：JP17331799

申请日：1999-06-18

Applicant: DAICEL CHEM

Inventor： SAKANE MASANORI ,  ITO MASAAKI

IPC: C08G63/08 ,  C08G63/78 ,  C08L101/16

Abstract: PROBLEM TO BE SOLVED: To stably produce a lactide-lactone copolymer excellent in heat resistance and impact resistance at a low cost by regulating the average chain length of the lactide-lactone copolymer so as to be within a specific range. SOLUTION: A remaining lactide (e.g. L-lactide) is added to a product during the polymerization or after finishing the polymerization of 2-85% lactide of the total lactide with a lactone (e.g. ε-caprolactone), and further polymerized to provide the objective lactide-lactone copolymer having >=3 (average) chain length of lactide units and 1-10 chain length of lactone units. The lactide units comprise random parts having =5 chain lengths, and the chain length 1LL(B) of the block part satisfies the inequality 1LL (B)2>[fL/(fL+fCap)]3×23 (fL is a lactone composition in the copolymer; fCap is a lactide composition).

公开(公告)号：JPH07324097A

公开(公告)日：1995-12-12

申请号：JP11725994

申请日：1994-05-30

Applicant: DAICEL CHEM ,  FUJISAWA PHARMACEUTICAL CO

Inventor： KAWAMOTO TAKAFUMI ,  ITO MASAAKI ,  KIMURA HITOSHI ,  SENOO HACHIRO ,  SEKI NOBUO

IPC: A61K38/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K5/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/52 ,  C07K14/54

Abstract: PURPOSE:To obtain a new peptide (salt) having a specific amino acid sequence, antagonistically acting on interleukin 6 (IL-6), inhibiting the active expression and useful for treating autoimmune diseases, etc. CONSTITUTION:These new peptides (salts) expressed by the formula X-W-Y (X is H, an amino-protecting group; Y is OH or a carboxy protecting group; W is a divalent group excluding one hydrogen atom from N end of a peptide continuously containing all or a part of an amino acid sequence expressed by formula I, formula II, etc.,and excluding OH from the C end of the peptide, with the proviso that a free mercapto group in the amino acid sequence may be protected) and suitable for treating autoimmune diseases, etc., as an interleukin 6 antagonist capable of inhibiting the expression of activity of interleukin 6 by antagonistically acting on interleukin 6. These peptides are obtained by using conventional peptide synthesis, e.g., solid phase synthetic method or liquid phase synthetic method.